Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Iopamidol
Drug ID BADD_D01181
Description Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Indications and Usage Not Available
Marketing Status approved
ATC Code V08AB04
DrugBank ID DB08947
KEGG ID D01797
MeSH ID D007479
PubChem ID 65492
TTD Drug ID D0O2HQ
NDC Product Code 68225-077; 0270-1412; 68225-078; 68225-100; 0270-1315; 0270-1317; 0270-1411; 70436-126; 62331-006; 0270-1316; 68225-076; 0270-1314; 70436-124; 57876-222
UNII JR13W81H44
Synonyms Iopamidol | Jopamidol | Gastromiro | Iopamidol, (+-)-Isomer | Iopamidol, (R)-Isomer | Iopamidol, Sodium Salt, (S)-Isomer | Iopamiro | Isovue 370 | Niopam | Solutrast | Solutrast 370 | Solutrast Gastro | SQ 13,396 | B-15,000 | B 15,000 | B15,000 | B-15000 | B 15000 | B15000 | Isovue
Chemical Information
Molecular Formula C17H22I3N3O8
CAS Registry Number 60166-93-0
SMILES CC(C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acute myocardial infarction24.04.04.001; 02.02.02.0010.010670%Not Available
Acute respiratory failure14.01.04.004; 22.02.06.0010.010670%Not Available
Agitation19.06.02.001; 17.02.05.012--
Amnesia19.20.01.001; 17.03.02.0010.015649%
Anaphylactic reaction24.06.03.006; 10.01.07.0010.235453%
Anaphylactic shock24.06.02.004; 10.01.07.0020.053350%Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.0030.024897%Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.051216%Not Available
Anuria20.01.03.002--Not Available
Anxiety19.06.02.0020.066155%
Aortic injury24.11.02.001; 12.01.11.005--
Aphasia19.21.01.001; 17.02.03.0010.010670%
Aphonia22.12.03.001; 19.19.01.002; 17.02.08.009--
Apnoea22.02.01.0010.010670%
Areflexia17.02.01.001--Not Available
Arrhythmia02.03.02.001--Not Available
Arterial spasm24.04.02.011--Not Available
Arterial thrombosis24.01.01.002--Not Available
Asphyxia22.02.02.001; 12.01.08.0110.014227%Not Available
Aspiration pleural cavity13.19.03.002--Not Available
Asterixis09.01.03.004; 17.01.06.001--Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Back pain15.03.04.005--
Blindness17.17.01.003; 06.02.10.003--Not Available
Blindness cortical06.02.10.004; 17.17.01.017--Not Available
Blindness transient06.02.10.006; 17.17.01.004--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene